SCHEMBL4684052

SCHEMBL4684052

ClC(N1CCCC1)=[N+]1CCCC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.35
ALDH1A1 P00352 3/20 0.32
MAPT P10636 2/20 0.32
HPGD P15428 2/20 0.32
KDM4E B2RXH2 1/20 0.32
TP53 P04637 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
ALOX15 P16050 1/20 0.32
ALOX12 P18054 1/20 0.32
NFKB1 P19838 1/20 0.32
MAPK1 P28482 1/20 0.32
CYP2C19 P33261 1/20 0.32
THPO P40225 1/20 0.32
MTOR P42345 1/20 0.32
NFKB2 Q00653 1/20 0.32
RELA Q04206 1/20 0.32
HIF1A Q16665 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27087843 0.97 F2 (0.33) F2ALDH1A1MAPTHPGDKDM4E
SCHEMBL13829458 0.97 F2 (0.39) F2ALDH1A1MAPTHPGDKDM4E
Hydrochloric Acid SCHEMBL17386512 0.95 F2 (0.37) F2ALDH1A1MAPTCA12CA1
SCHEMBL152188 0.91 F2 (0.30) F2
SCHEMBL20578267 0.91 F2 (0.30) F2
SCHEMBL25257397 0.89 F2 (0.33) F2ALDH1A1
SCHEMBL597131 0.89 F2 (0.33) F2ALDH1A1
SCHEMBL22194142 0.84 MAPT (0.33) MAPT
SCHEMBL13319270 0.81 MEN1 (0.39) ALDH1A1HPGDTP53HSD17B10CA12
SCHEMBL13864168 0.72 ALDH1A1 (0.35) F2ALDH1A1MAPTHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624011-B2 Oxadiazole derivative Sumitomo Pharma Co., Ltd. (JP) 2026-05-12 US disclosed
EP-4122923-B1 OXADIAZOLE DERIVATIVE SUMITOMO PHARMA CO LTD (JP) 2025-09-10 EP disclosed
US-20250197353-A1 METHOD OF FORMING BOND BY COUPLING REACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-06-19 US disclosed
EP-4387980-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2024-06-26 EP disclosed
EP-4320107-A1 DOPANTS FOR ELECTRONIC COMPONENTS, THEIR USE IN ELECTRONIC COMPONENTS, AND ELECTRONIC COMPONENTS WITH SUCH DOPANTS Heliatek GmbH (DE) 2024-02-14 EP disclosed
US-11833219-B2 Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof MABPLEX INTERNATIONAL CO., LTD. (CN) 2023-12-05 US disclosed
US-20230265061-A1 OXADIAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-08-24 US disclosed
US-11718592-B2 Oxadiazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-08-08 US disclosed
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
US-20230203484-A1 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
US-8309294-B2 2012-11-13 US disclosed
US-7829270-B2 Photosensitive material, method of manufacturing conductive metal film, conductive metal film and light-transmitting film shielding electromagnetic wave for plasma display panel FUJIFILM CORPORATION (JP) 2010-11-09 US disclosed
US-7829270-B2 Photosensitive material, method of manufacturing conductive metal film, conductive metal film and light-transmitting film shielding electromagnetic wave for plasma display panel FUJIFILM CORPORATION (JP) 2010-11-09 US disclosed
US-20090268186-A1 PATTERN EXPOSURE METHOD AND PATTERN EXPOSURE APPARATUS FUJIFILM CORPORATION (JP) 2009-10-29 US disclosed
US-20090268186-A1 PATTERN EXPOSURE METHOD AND PATTERN EXPOSURE APPARATUS FUJIFILM CORPORATION (JP) 2009-10-29 US disclosed
US-20090017277-A1 comprising a support; and an emulsion layer containing a silver salt emulsion, the photosensitive material being capable of forming a conductive metal film by exposing and developing the emulsion layer, wherein the emulsion layer has a swelling rate of 150% or more FUJIFILM CORPORATION (JP) 2009-01-15 US disclosed
US-20090017277-A1 comprising a support; and an emulsion layer containing a silver salt emulsion, the photosensitive material being capable of forming a conductive metal film by exposing and developing the emulsion layer, wherein the emulsion layer has a swelling rate of 150% or more FUJIFILM CORPORATION (JP) 2009-01-15 US disclosed
US-20080318155-A1 LITHOGRAPHIC PRINTING PLATE PRECURSOR AND PLATE MAKING METHOD FUJIFILM CORPORATION (JP) 2008-12-25 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718592-B2 Oxadiazole derivative OXA1L, SCN1A, CACNA1A F2 1252/4885ALDH1A1 305/4885MAPT 1620/4885
US-11833219-B2 Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof AURKA, AURKC, CA14 F2 2663/4885ALDH1A1 282/4885MAPT 886/4885
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF RNGTT, NSUN2, ALKBH1 F2 4870/4885ALDH1A1 1901/4885MAPT 4649/4885
US-20230265061-A1 OXADIAZOLE DERIVATIVE OXA1L, SCN1A, CACNA1A F2 1252/4885ALDH1A1 305/4885MAPT 1620/4885
US-12624011-B2 Oxadiazole derivative HSD3B1, CBR3, CBR1 F2 2304/4885ALDH1A1 568/4885MAPT 4111/4885
US-20250197353-A1 METHOD OF FORMING BOND BY COUPLING REACTION CBR1, CBR3, NOX4 F2 9/4885ALDH1A1 1855/4885MAPT 4530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.